News | July 02, 2021
Sandu Pharmaceuticals Q4FY21 PAT at Rs. 46.14 lakhs
The company has posted net profit of Rs.1.09 crores for the 12 months period ended March 31, 2021
The company has posted net profit of Rs.1.09 crores for the 12 months period ended March 31, 2021
Sun Pharma has committed Rs. 100 crores towards these initiatives
ZyCoV-D had already exhibited a robust immunogenicity and tolerability and safety profile in the adaptive Phase I/II clinical trials
The company has reported total income of Rs.355.43 crores during FY 2020-21
2-DG was developed by the Institute of Nuclear Medicine & Allied Sciences (INMAS), a laboratory of the Defence Research and Development Organisation (DRDO), in collaboration with Dr. Reddy's
The company has now received the renewed GMP (Good Manufacturing Practices) certificate thereby confirming the successful closure of the inspection
The company has posted net profit of Rs.12.12 crores for the 12 months period ended March 31, 2021
2DG has been given emergency approval by the Drug Controller General of India for COVID-19 patients in the country
Entered into a manufacturing partnership with Ocugen, Inc. for manufacturing of COVID-19 vaccine COVAXIN for the US and Canadian markets
The company recorded revenue of Rs 528crore as compared to Rs 444 crore, registering a growth of 19% over the corresponding quarter ended 31st March 2020
Subscribe To Our Newsletter & Stay Updated
